Hoth Phase 2a: 100% Success in Combating Cancer Treatment Skin Toxicities

 

• 100% of Patients in Cohort 1 Achieve Primary Efficacy Endpoint
• No Treatment-Related Adverse Effects Observed
• Preserves Cancer Treatment Efficacy with Zero Dose Reductions

https://www.prnewswire.com/news-releases/hoth-therapeutics-achieves-breakthrough-in-phase-2a-trial-ht-001-delivers-100-success-in-combating-cancer-treatment-skin-toxicities-302344046.html